色酮
化学
单胺氧化酶
甲酰胺
药品
立体化学
药理学
铅化合物
IC50型
单胺氧化酶B
化学合成
药物发现
结构-活动关系
体外
生物化学
酶
医学
作者
Joana Reis,Carlos Fernandes,Hoda A. Salem,Marta Maia,Cláudia Tomé,Sofia Benfeito,José Teixeira,Paulo J. Oliveira,Eugenio Uriarte,Francesco Ortuso,Stefano Alcaro,Donatella Bagetta,Fernando Cagide,Fernanda Borges
标识
DOI:10.1016/j.ejmech.2022.114507
摘要
The absence of disease modifying drugs in Parkinson's disease therapy urges for new chemical entities acting on relevant PD-associated biological targets. As a result, developing selective and reversible inhibitors targeting MAO-B is still a desirable line of therapeutic research. Within this framework, a small library of chromone derivatives was synthesized and screened towards human monoamine oxidases. Structural modifications on the chromone 3-phenylcarboxamide resulted in potent MAO-B inhibitors with an improved drug-like profile, and for the first time we obtained potent and selective chromone 2-phenylcarboxamides acting in the low nanomolar range. Compounds 5-hydroxy-4-oxo-N-phenyl-4H-chromene-3-carboxamide (38) (IC50 = 13.0 nM) and N-(4-chlorophenyl)-5-hydroxy-4-oxo-4H-chromene-3-carboxamide (41) (IC50 = 8.3 nM) stood out as reversible, potent, selective and non-cytotoxic MAO-B inhibitors bearing a favourable drug-like profile. Both compounds displayed cytoprotective effects towards iron(III) oxidative stressor.
科研通智能强力驱动
Strongly Powered by AbleSci AI